Clinical Trials › NCT06486779
Recruiting
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
Sponsored by Novartis Pharmaceuticals
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 160
Target enrollment
Dec 2024
Start date
Dec 2028
Expected completion
Interventions / Treatments
Ofatumumab
Conditions studied
Relapsing Multiple Sclerosis (RMS)
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
The app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.